Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527601 | 0.77 | — | — | |
| SCHEMBL1068717 | 0.73 | CA2 (0.34) | TAS2R14 | |
| SCHEMBL526140 | 0.72 | FABP4 (0.37) | — | |
| SCHEMBL8084518 | 0.71 | — | — | |
| SCHEMBL6228844 | 0.69 | — | — | |
| SCHEMBL455888 | 0.68 | EPHX2 (0.31) | — | |
| SCHEMBL1844307 | 0.67 | — | — | |
| SCHEMBL1041748 | 0.67 | TAS2R14 (0.46) | TAS2R14 | |
| SCHEMBL147747 | 0.67 | — | — | |
| SCHEMBL25277776 | 0.65 | NOTUM (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103261198-A | 2-arylimidazo[1,2-]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives | JIANGSU HENGRUI MEDICINE CO | 2013-08-21 | — | — | CN | disclosed |
| US-7951602-B2 | Mass defect labeling and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | PTMS, SPPL2B, NPPA | TAS2R14 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.